Polaryx Therapeutics (PLYX) Company presentation summary

Strategic focus and market opportunity

• Dedicated to developing disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs), targeting highly unmet orphan indications.

• Aims to establish new standards of care and unlock multi-billion-dollar opportunities in the LSD market.

• Employs robust strategies for topline data readouts and commercialization, leveraging expedited regulatory pathways.

• Proprietary oral formulations and strong IP protection support patient-friendly treatments and market differentiation.

Pipeline and clinical development

• Lead candidate PLX-200 is an oral small molecule, repurposed and IND-approved, targeting multiple LSDs via a basket trial design.

• PLX-200 activates PPARα, promoting lysosome biogenesis and anti-inflammatory gene expression, with proven efficacy in animal models of CLN2, CLN3, Krabbe, and Sandhoff diseases.

• Additional pipeline assets include PLX-300 (novel small molecule), PLX-100 (combination therapy), and PLX-400 (gene therapy), all in preclinical or IND-enabling stages.

• SOTERIA Phase 2 basket trial is prioritized for its flexible, catalyst-rich design, evaluating PLX-200 across four LSD indications.

Proof of concept and preclinical data

• PLX-200 demonstrated increased TFEB expression and reduced storage material in CLN3 animal models.

• Improved locomotor abilities, life expectancy, and survival in CLN2, Sandhoff, and Krabbe disease models.

• Reduced glycoconjugate and psychosine accumulation, alleviating motor deficits and extending lifespan in relevant models.